SuPAR as a prognostic biomarker in sepsis

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Donadello, Katia ^a   Scolletta, Sabino ^a   Covajes, Cecilia ^a   Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Biomarker; Case fatality; Disease severity; Infection; Outcome; Sepsis; Soluble urokinase type plasminogen activator receptor; Supar

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UROKINASE RECEPTOR; CALCITONIN; PROCALCITONIN; PROTEIN PRECURSOR;

BACTERIAL MENINGITIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CEREBROSPINAL FLUID; CHEMOTAXIS; CRIMEAN CONGO HEMORRHAGIC FEVER; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTION; HEMORRHAGIC FEVER; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LIVER FUNCTION; MALARIA; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PNEUMOCOCCAL INFECTION; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; SEPSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; STAPHYLOCOCCAL BACTEREMIA; STREPTOCOCCUS INFECTION; TUBERCULOSIS; UROSEPSIS; VIRUS MENINGITIS; BLOOD; DISEASE COURSE; EARLY DIAGNOSIS; METABOLISM; PREDICTIVE VALUE; REVIEW;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SEPSIS;

EID: 84855381301     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-2     Document Type: Short Survey

References (39)

1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256. 10.1097/01.CCM.0000050454.01978.3B, 12682500.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
3. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437.
4. Marshall JC, Reinhart K. Biomarkers of sepsis. Crit Care Med 2009, 37:2290-2298. 10.1097/CCM.0b013e3181a02afc, 19487943.
5. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010, 14:R15. 10.1186/cc8872, 2875530, 20144219.
6. Vincent JL, Donadello K, Schmit X. Biomarkers in the critically ill patient: C-reactive protein. Crit Care Clin 2011, 27:241-251. 10.1016/j.ccc.2010.12.010, 21440199.
7. Schuetz P, Albrich WC, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 2011, 9:107. 10.1186/1741-7015-9-107, 3186747, 21936959.
8. Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011, 270:32-40. 10.1111/j.1365-2796.2011.02363.x, 21332843.
9. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990, 9:467-474. 551688, 1689240.
10. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991, 266:1926-1933.
11. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009, 27:157-172.
12. Eugen-Olsen J. suPAR as a marker of disease severity and risk of mortality in sepsis. J Intern Med 2011, 270:29-31. 10.1111/j.1365-2796.2011.02372.x, 21366732.
13. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, Dybkjaer E, Dano K, Brunner N. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997, 43:1868-1876.
14. Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, Eugen-Olsen J. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004, 10:409-415. 10.1111/j.1469-0691.2004.00850.x, 15113317.
15. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995, 86:203-211.
16. Ostrowski SR, Plomgaard P, Fischer CP, Steensberg AS, Moller K, Hoyer-Hansen G, Pedersen BK, Ullum H. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells. Scand J Immunol 2005, 61:197-206. 10.1111/j.0300-9475.2005.01547.x, 15683457.
17. Dekkers PE, ten Hove T, te Velde AA, van Deventer SJ, van der PT. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect Immun 2000, 68:2156-2160. 10.1128/IAI.68.4.2156-2160.2000, 97398, 10722614.
18. Juffermans NP, Dekkers PE, Verbon A, Speelman P, van Deventer SJ, van der PT. Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia. Infect Immun 2001, 69:5182-5185. 10.1128/IAI.69.8.5182-5185.2001, 98617, 11447203.
19. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994, 79:1605-1608. 10.1210/jc.79.6.1605, 7989463.
20. de Kruif MD, Lemaire LC, Giebelen IA, Struck J, Morgenthaler NG, Papassotiriou J, Elliott PJ, van der PT. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008, 34:518-522. 10.1007/s00134-007-0955-x, 2244699, 18080111.
21. Kemna E, Pickkers P, Nemeth E, van der HH, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005, 106:1864-1866. 10.1182/blood-2005-03-1159, 15886319.
22. Yilmaz G, Mentese A, Kaya S, Uzun A, Karahan SC, Koksal I. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever. J Clin Virol 2011, 50:209-211. 10.1016/j.jcv.2010.11.014, 21167774.
23. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, Larsen K. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007, 11:R38. 10.1186/cc5723, 2206456, 17362525.
24. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004, 36:14-19. 10.1080/00365540310017366, 15000553.
25. Winkler F, Kastenbauer S, Koedel U, Pfister HW. Role of the urokinase plasminogen activator system in patients with bacterial meningitis. Neurology 2002, 59:1350-1355.
26. Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011, 15:R63. 10.1186/cc10037, 3221996, 21324198.
27. Donadello K, Covajes C, Scolletta S, Taccone FS, Santonocito C, Brimioulle S, Beumier M, Vannuffelen M, Gottin L, Vincent JL. Clinical value of suPAR, a new biomarker. Intensive Care Med 2011, 37:S199. (abst).
28. Ostrowski SR, Ullum H, Goka BQ, Hoyer-Hansen G, Obeng-Adjei G, Pedersen BK, Akanmori BD, Kurtzhals JA. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005, 191:1331-1341. 10.1086/428854, 15776381.
29. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002, 6:686-692.
30. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:23-31. 10.1097/01.qai.0000157950.02076.a6, 15851910.
31. Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G. Correlates for disease progression and prognosis during concurrent HIV/TB infection. Int J Infect Dis 2007, 11:289-299. 10.1016/j.ijid.2007.02.001, 17446108.
32. Lawn SD, Myer L, Bangani N, Vogt M, Wood R. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. BMC Infect Dis 2007, 7:41. 10.1186/1471-2334-7-41, 1885800, 17509133.
33. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000, 96:4091-4095.
34. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 2008, 27:375-383. 10.1007/s10096-007-0447-5, 18197443.
35. Florquin S, van den Berg JG, Olszyna DP, Claessen N, Opal SM, Weening JJ, van der PT. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 2001, 59:2054-2061.
36. Molkanen T, Ruotsalainen E, Thorball CW, Jarvinen A. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2011, 30:1417-1424. 10.1007/s10096-011-1236-8, 21479972.
37. Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, Schroeder S. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009, 13:R83. 10.1186/cc7903, 2717450, 19493352.
38. Ostrowski SR, Ravn P, Hoyer-Hansen G, Ullum H, Andersen AB. Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy. Scand J Infect Dis 2006, 38:1028-1032. 10.1080/00365540600868305, 17148072.
39. Perch M, Kofoed P, Fischer TK, Co F, Rombo L, Aaby P, Eugen-Olsen J. Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 2004, 26:207-211. 10.1111/j.0141-9838.2004.00695.x, 15491469.